Can a targeted drug beat radiation for early-stage lymphoma?
Disease control
Not yet recruiting
This phase 3 trial compares the experimental drug surovatamig with standard involved-site radiotherapy (with or without rituximab) in people with limited-stage follicular lymphoma. The goal is to see if surovatamig can produce deeper, longer-lasting responses and reduce the chanc…
Phase: PHASE3 • Sponsor: Australasian Leukaemia and Lymphoma Group • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC